Asset Details
Do you wish to reserve the book?
Targeting inflammation as a treatment modality for neuropathic pain in spinal cord injury: a randomized clinical trial
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Targeting inflammation as a treatment modality for neuropathic pain in spinal cord injury: a randomized clinical trial
Do you wish to request the book?
Targeting inflammation as a treatment modality for neuropathic pain in spinal cord injury: a randomized clinical trial
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Targeting inflammation as a treatment modality for neuropathic pain in spinal cord injury: a randomized clinical trial
2016
Overview
Background
The purpose of the present study was to examine the effectiveness of an anti-inflammatory intervention as a treatment for neuropathic pain following spinal cord injury (SCI).
Methods
This randomized, parallel-group, controlled clinical trial (NCT02099890) examined 20 participants with varying levels and severities of SCI, randomized (3:2) to either a 12-week anti-inflammatory diet, or control group. Outcome measures consisted of self-determined indices of pain as assessed using the neuropathic pain questionnaire (NPQ) and markers of inflammation as assessed by various pro- and anti-inflammatory cytokines, as well as the eicosanoids PGE2 and LTB4.
Results
A significant group × time interaction was found for sensory pain scores (
p
< 0.01). A Mann-Whitney test revealed that the change scores (3-month baseline) were significantly different between groups for IFN-y (
U
= 13.0,
p
= 0.01), IL-1β (
U
= 14.0,
p
= 0.01), and IL-2 (
U
= 12.0,
p
= 0.01). A Friedman test revealed the treatment group had a significant reduction in IFN-y (
x
2
= 8.67,
p
= 0.01), IL-1β (
x
2
= 17.78,
p
< 0.01), IL-6 (
x
2
= 6.17,
p
< 0.05), while the control group showed no significant change in any inflammatory mediator. A stepwise backward elimination multiple regression analysis showed that the change in sensory neuropathic pain was a function of the change in the proinflammatory cytokines IL-2 and IFN-y, as well as the eicosanoid PGE2 (
R
= 0.689,
R
2
= 0.474).
Conclusions
Overall, the results of the study demonstrate the efficacy of targeting inflammation as a means of treating neuropathic pain in SCI, with a potential mechanism relating to the reduction in proinflammatory cytokines and PGE2.
Trial registration
ClinicalTrials.gov,
NCT02099890
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V
Subject
/ Aged
/ Antioxidants - administration & dosage
/ Biomedical and Life Sciences
/ Complications and side effects
/ Diet, Carbohydrate-Restricted - methods
/ Diet, Protein-Restricted - methods
/ Female
/ Humans
/ Inflammation Mediators - antagonists & inhibitors
/ Inflammation Mediators - blood
/ Male
/ Spinal Cord Injuries - blood
/ Spinal Cord Injuries - diagnosis
